Q2 2026 Highlights

July 29, 2026

Forward-Looking Statements and Use of Document

Forward-looking statements:
This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; adjusted EPS for the third quarter and full year 2026; free cash flow (FCF); adjusted expenses; tax rates; our financial performance; acquisitions; clinical trials; our business plans and product performance; market sizes and growth rates; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this presentation. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences can be found in our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed or to be filed with the Securities and Exchange Commission under the headings "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements." Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law.

Market estimates:
Unless noted otherwise, all references to market sizes, market share positions, and market growth rates are BSX internal estimates.

Non-GAAP Measures:
This document contains non-generally accepted accounting principles in the United States (GAAP) measures (denoted with *) in talking about our Company's performance. The reconciliations of these non-GAAP measures to their most comparable GAAP measures are contained within this document including appendices attached to the end of this presentation or in our earnings release.

Operational net sales growth excludes the impact of foreign currency fluctuations. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.

We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all based on internally-derived standard currency exchange rates to exclude the impact of foreign currency, which may be updated from year to year. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments considered to be non-operational. Please refer to Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission or Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations in our Quarterly Reports on Form 10-Q that we have filed or will file thereafter for an explanation of each of these adjustments and the reasons for excluding each item.

Adjusted EPS excludes the impact of certain charges (credits) which may include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), European Union (EU) Medical Device Regulation (MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits), discrete tax items and other charges (credits) as appropriate.

FCF is a non-GAAP measure calculated as operating cash flows less net purchases of property, plant and equipment and internal use software.

Operational Structure:
In the fourth quarter of 2025, an organizational change combined our legacy Cardiology and Peripheral Interventions businesses into a single Cardiovascular business. All prior period amounts have been revised to conform to current year presentation. This change had no impact on our reportable segments.

Use of Document:
This document contains certain highlights with respect to our second quarter 2026 performance and developments and does not purport to be a complete summary thereof. Accordingly, we encourage you to read our Earnings Release for the quarter ended June 30, 2026 located in the investor section of our website at www.bostonscientific.com and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 to be filed with the Securities and Exchange Commission.

Amounts reported in millions within this presentation are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.

Q2 2026 Highlights

Financial Highlights

- **Net sales growth:**
  - +7.5% reported, +7.0% operational*/organic* Y/Y
- **Earnings per share:**
  - As reported: $0.61 vs. $0.53 Q2:25
  - Adjusted*: $0.86 vs. $0.75 Q2:25
- **Gross margin:**
  - As reported: 70.7%, +300 bps Y/Y
  - Adjusted*: 70.3%, +80 bps Y/Y
- **Operating margin:**
  - As reported: 21.6%, +550 bps Y/Y
  - Adjusted*: 28.4%, +70 bps Y/Y
- **Q3 2026 guidance vs. Q3 2025:**
  - As reported net sales growth: 3.0% - 5.0%
  - Organic* net sales growth: 3.0% - 5.0%
  - Adjusted EPS*: $0.80 - $0.82
- **FY 2026 guidance vs. FY 2025:**
  - As reported net sales growth: 5.5% - 6.5%
  - Organic* net sales growth: 5.0% - 6.0%
  - Adjusted EPS*: $3.28 - $3.32

Operational Highlights

- Completed the previously announced $2 billion accelerated share repurchase program, repurchasing approximately 40 million shares.
- Invested $1.5 billion in **MiRus LLC**, which is developing and commercializing proprietary biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the **SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system**, in return for an equity stake of approximately 34% and exclusive option to acquire the MiRus TAVR business.[1]
- Presented late-breaking findings at EuroPCR from the FRACTURE Investigational Device Exemption trial, which met its primary endpoints with the **SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter**, demonstrating high rates of freedom from major adverse cardiac events at 30 days as well as procedural success in patients with severely calcified coronary artery disease.[1]
- Announced clinical trial results that were presented in late-breaking sessions at Heart Rhythm 2026 including:
  - The AVANT GUARD study of **FARAPULSE™ Pulsed Field Ablation (PFA)** for the treatment of persistent atrial fibrillation (AF) in patients who had not previously been treated for their condition. Data met all safety and effectiveness endpoints and demonstrated statistical superiority of FARAPULSE PFA over anti-arrhythmic drugs with significantly higher primary effectiveness.
  - The ELEVATE-PF feasibility study of the **FARAFLEX™ Mapping and PFA Catheter** — a novel large focal, high-density map-and-ablate catheter — in patients with paroxysmal and persistent AF. The trial demonstrated strong lesion durability validated by cardiac remapping, with no reported cases of pulmonary vein stenosis, hemolysis, coronary spasm or clinical stroke.[1]
- Commenced enrollment in the pivotal FARADIGM clinical trial to evaluate the safety and effectiveness of the **FARAFLEX Mapping and PFA Catheter** for treating patients with paroxysmal and persistent AF.[1]

1. The SIEGEL Balloon Expandable TAVR system, the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter and the FARAFLEX Mapping and PFA Catheter are investigational devices. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.

Reported Net Sales by Segment and Business

Q2 2026 Reported Net Sales: $5.442B

Net Sales by Business; Segment Percentage of Total Net Sales

MedSurg
33%





Cardiovascular
67%

MedSurg Performance Summary

Measure	Q2 2026	Q2 2025	Change Y/Y
Reported Net Sales	$1.818B	$1.716B	+5.9%
Adjusted Operating Margin*	32.9%	35.1%	(230 bps)

* Represents operating income as a percentage of operational net sales, both based on internally-derived standard currency exchange rates to exclude the impact of foreign currency, which may be updated from year to year. This measure is reported to the chief operating decision maker (CODM) for purposes of making decisions about allocating resources to the segment and assessing its performance. Prior period adjusted operating margin has been restated at constant currency rates to conform to current year presentation.

Q2 2026 Highlights

- **Endoscopy: Global net sales +7.6% as reported, +7.0% operational*/organic***
  - Growth driven by better than anticipated performance from AXIOS. Within the quarter, received FDA clearance for RIVOS, a first-of-its-kind single-device designed to streamline procedural steps while performing Endoscopic Ultrasound biliary drainage.
- **Urology: Global net sales +1.1% as reported, +0.8% operational*/organic***
  - Underperformance in the quarter driven by Sacral Neuromodulation, with a slower recovery than anticipated and Stone, where we continue to face competitive pressures with key portfolio gaps.
- **Neuromodulation: Global net sales +12.7% as reported, +12.2% operational*/organic***
  - Pain franchise grew low double-digits, with strong growth across the portfolio including a full quarter of contribution from Nalu, which performed well in Q2.
  - Brain grew low double-digits, with strong growth across the globe enabled by our innovative portfolio.

Cardiovascular Performance Summary

Measure	Q2 2026	Q2 2025	Change Y/Y
Reported Net Sales	$3.624B	$3.345B	+8.3%
Adjusted Operating Margin*	33.1%	32.1%	+100 bps

* Represents operating income as a percentage of operational net sales, both based on internally-derived standard currency exchange rates to exclude the impact of foreign currency, which may be updated from year to year. This measure is reported to the CODM for purposes of making decisions about allocating resources to the segment and assessing its performance. Prior period adjusted operating margin has been restated at constant currency rates to conform to current year presentation.

Q2 2026 Highlights

- **Cardiovascular: Global net sales +8.3% as reported, +7.8% operational*/organic***
  - **Interventional Cardiology & Vascular Therapies: Global net sales +13.1% as reported, +12.1% operational*/organic***
    - Interventional Cardiology organic growth of 15% was driven by double digit growth in Coronary Therapies, with exceptional strength in AGENT DCB.
    - Vascular Therapies grew 8% organically, driven by broader adoption of Varithena and our drug-eluting portfolio.
  - **Watchman: Global net sales +4.3% as reported, +4.2% operational*/organic***
    - U.S. grew +3% organically, while International grew +18% organically. WATCHMAN underperformed expectations in the quarter as the LAAC market slowed primarily driven by compounding clinical evidence impacting referral patterns.
  - **Electrophysiology: Global net sales +9.1% as reported/operational*/organic***
    - U.S. grew +3% organically, while International grew +23% organically. Growth driven by our differentiated PFA ecosystem partially offset by competitive pressures in U.S. market.
  - **Cardiac Rhythm Management: Global net sales (0.9)% as reported, (1.6)% operational*/organic***
    - Low-voltage declined high-single-digits and high-voltage declined mid-single digits, driven by competitive pressures with key portfolio gaps. Diagnostics grew low-double digits.
  - **Interventional Oncology & Embolization: Global net sales +12.9% as reported, +11.8% operational*/organic***
    - Driven by strong global growth with our broad offering of innovative technologies.

Key Growth Catalysts

Select new products and data releases

Product Launched | Product Launch Expected | Data Release

		2026	2027E	2028E
Cardiovascular				
ICVT		FRACTURE (Coronary IVL)	SEISMIQ™ Coronary IVL	
		SEISMIQ™ Above-the-Knee IVL; SEISMIQ™ Below-the-Knee IVL	THRIVE (RDN)	TIVUS™ Intravascular Ultrasound System (RDN)
WM		CHAMPION AF Q1:26	Imaging 4D ICE	WATCHMAN™ Elite
CRM			EMPOWER & mCRM™; LUX-AIR™ICM System; PRECEDENT™ next-gen defib	
EP		FARAPOINT™; OPAL Software Launches	FARAWAVE™ ULTRA; CHORUS IDx™ | 2D ICE; REMATCH-AF	FARAFLEX™
IO&E		TheraSphere™ 360 + Any Day dosing; TruSelect™ 2.6 Microcatheter	ROWAN TheraSphere™ combination therapy	
MedSurg				
Endo		Rivos™ Biliary Access Device	Versatile™	
Uro		Asurys™ Fluid mgmt; eCoin® system Tibial Nerve Stim; Slim Scope	Suction Sheath	
NM		Edge J stylet Next-gen Intracept™; Nalu Neurostimulation peripheral nerve stimulation		Next-gen spinal cord stimulation

Timeline represents expected launch timing or data presentation. Select product launches and data releases, list is not comprehensive.

Future of Innovation

Unlocking New Markets for BSX

Product	2025E Market Size Market Growth	2026E	2027E	2028E	2029E
RDN Renal Denervation	$1B+ +DD 2028E		THRIVE Data Release	TIVUS™ Launch	
IVL Intravascular Lithotripsy	$1B+ +DD	SEISMIQ™ Peripheral ATK Launch; SEISMIQ™ Peripheral BTK Launch	SEISMIQ™ 4CE Coronary Launch		
ICE (EP) Intracardiac Echocardiography	$1.3B +DD		2D ICE / OPAL Integration		
ABLATION Complex Arrhythmias	$3B+ +DD	FARADIGM FPI	FARADIGM Data	FARAFLEX™ Launch	
CIRC SUPPORT	$1.5B +DD	Global IDE FPI		VITALYST™ Launch	
EXTERNAL					
PENUMBRA[1] Neurovascular & Thrombectomy	11%	Expected Close			
MiRus[2] TAVR	$7B+ +HSD	STAR Trial FPI; BSX Investment Announced			SIEGEL™ Valve Launch

[1] Signed, not yet closed; anticipate closing in H2 2026.
[2] Investigational device. Limited by Federal Law to investigational use only. Not available for sale.

Timeline represents expected launch timing or data presentation. Select product launches and data releases, list is not comprehensive.

Our Approach to Corporate Responsibility

Boston Scientific

Innovative care

We shape science into meaningful solutions that help people live longer, better lives.

Empowered people

We invest in our people and unite our diverse communities through global collaboration.

Healthier planet

We confront climate change and protect the environment to enable people to live healthier lives.

Performance with integrity

Governance and compliance | Risk management | Cybersecurity | Responsible supply chain

Q2 2026 Net Sales vs. Q2 2025

(in millions, except percentages)	Q2 2026 Reported Net Sales	Organic* Growth vs Q2 2025
Endoscopy	$793	7%
Urology	$684	1%
Neuromodulation	$341	12%
MedSurg	**$1,818**	**5%**
Interventional Cardiology and Vascular Therapies	*$1,333*	*12%*
Watchman	*$507*	*4%*
Electrophysiology	*$916*	*9%*
Cardiac Rhythm Management	*$585*	*(2)%*
Interventional Oncology & Embolization	*$283*	*12%*
Cardiovascular	**$3,624**	**8%**
Total Company	**$5,442**	**7%**
Guidance Range *Disclosed April 22, 2026*		**5 to 7 percent**

Income Statement Information

Non-GAAP Reconciliation

Three Months Ended June 30, 2026 (unaudited)

in millions, except per share data	GAAP Results	Amortization Expense	Acquisition/ Divestiture-Related Net Charges/ Credits	Restructuring and Restructuring-Related Net Charges/ Credits	Litigation-Related Net Charges/ Credits	Investment Portfolio Net Losses/ Gains and Impairments	EU MDR Implementation Costs	International Emergency Economic Powers Act (IEEPA) tariff refund	Deferred Tax Expenses/ Benefits	Adjusted* Results
Net sales	**$ 5,442**	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —	**$ 5,442**
Cost of products sold (excluding amortization expense)	1,594	—	30	25	—	—	4	(83)	—	1,618
Gross profit	**3,848**	**—**	**(30)**	**(25)**	**—**	**—**	**(4)**	**83**	**—**	**3,824**
Gross margin	*70.7 %*									*70.3 %*
Selling, general and administrative expenses	1,803	—	35	8	—	—	0	—	—	1,760
SG&A as a percentage of sales	*33.1 %*									*32.3 %*
Research and development expenses	554	—	42	0	—	—	3	—	—	509
R&D as a percentage of sales	*10.2 %*									*9.4 %*
Royalty expense	12	—	—	—	—	—	—	—	—	12
Royalty expense as a percentage of sales	*0.2 %*									*0.2 %*
Amortization expense	233	233	—	—	—	—	—	—	—	—
Contingent consideration net expense (benefit)	(16)	—	(16)	—	—	—	—	—	—	—
Restructuring net charges (credits)	8	—	—	8	—	—	—	—	—	—
Litigation-related net charges (credits)	76	—	—	—	76	—	—	—	—	—
	2,670	233	61	16	76	—	3	—	—	2,281
Operating income (loss)	**1,178**	**(233)**	**(91)**	**(42)**	**(76)**	**—**	**(7)**	**83**	**—**	**1,543**
Operating margin	*21.6 %*									*28.4 %*
Other income (expense):										
Interest expense	(96)	—	(1)	—	—	—	—	—	—	(95)
Other, net	(23)	—	—	—	—	2	—	—	—	(25)
Income (loss) before income taxes	**1,060**	**(233)**	**(92)**	**(42)**	**(76)**	**2**	**(7)**	**83**	**—**	**1,423**
Income tax expense (benefit)	155	(27)	(20)	(5)	(16)	0	(1)	7	70	148
Net income (loss)	**905**	**(206)**	**(72)**	**(37)**	**(60)**	**2**	**(6)**	**77**	**(70)**	**1,275**
Net income (loss) attributable to noncontrolling interests	**(2)**	**(2)**	—	—	—	—	—	—	—	**1**
Net income (loss) attributable to Boston Scientific common stockholders	**$ 907**	**$ (203)**	**$ (72)**	**$ (37)**	**$ (60)**	**$ 2**	**$ (6)**	**$ 77**	**$ (70)**	**$ 1,275**
Net income (loss) per diluted common share	**$ 0.61**	**$ (0.14)**	**$ (0.05)**	**$ (0.02)**	**$ (0.04)**	**$ 0.00**	**$ (0.00)**	**$ 0.05**	**$ (0.05)**	**$ 0.86**
Weighted average diluted shares outstanding	**1,474.8**	**1,474.8**	**1,474.8**	**1,474.8**	**1,474.8**	**1,474.8**	**1,474.8**	**1,474.8**	**1,474.8**	**1,474.8**

Working Capital & Cash Flow Metrics

Days Sales Outstanding (DSO)

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025
51	52	51	51	51

Free Cash Flow*

Q2 2026	Q2 2025
$1.290B	$1.129B

Days Inventory on Hand (DIOH)

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025
185	177	168	177	159

Capital Expenditures

Q2 2026	Q2 2025
$194M	$157M

Use of Non-GAAP Measures

To supplement Boston Scientific's consolidated financial statements presented on a GAAP basis, the Company discloses certain non-GAAP financial measures. These measures are not in accordance with generally accepted accounting principles in the United States.

A reconciliation of these measures to the corresponding GAAP measures follows in the Appendices. In addition, an explanation of the ways in which Boston Scientific management uses these supplemental non-GAAP measures to evaluate its business and the substantive reasons why Boston Scientific management believes that these measures provide useful information to investors is included under "Use of Non-GAAP Financial Measures" in the Company's most recent earnings release filed with the SEC on Form 8-K. This information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP.

Appendix A
Net Sales Detail

Appendix A - Net Sales Detail - MedSurg

Three Months Ended June 30, 2026 and 2025

(in millions, except percentages)	Q2 2026	Q2 2025	Year-over-Year Change: Reported Basis	Year-over-Year Change: Impact of Foreign Currency Fluctuations	Year-over-Year Change: Operational Basis
MEDSURG SEGMENT:					
ENDOSCOPY					
UNITED STATES	$ 491	$ 456	7.6 %	— %	7.6 %
INTERNATIONAL	303	281	7.7 %	(1.7)%	6.0 %
WORLDWIDE	**$ 793**	**$ 737**	**7.6 %**	**(0.7)%**	**7.0 %**
UROLOGY					
UNITED STATES	$ 503	$ 499	0.8 %	— %	0.8 %
INTERNATIONAL	181	178	1.9 %	(1.2)%	0.7 %
WORLDWIDE	**$ 684**	**$ 676**	**1.1 %**	**(0.3)%**	**0.8 %**
NEUROMODULATION					
UNITED STATES	$ 257	$ 228	13.1 %	— %	13.1 %
INTERNATIONAL	84	75	11.8 %	(2.4)%	9.4 %
WORLDWIDE	**$ 341**	**$ 303**	**12.7 %**	**(0.6)%**	**12.2 %**

Appendix A - Net Sales Detail - Cardiovascular
Three Months Ended June 30, 2026 and 2025

(in millions, except percentages)	Q2 2026	Q2 2025	Year-over-Year Change: Reported Basis	Year-over-Year Change: Impact of Foreign Currency Fluctuations	Year-over-Year Change: Operational Basis
CARDIOVASCULAR SEGMENT:					
Interventional Cardiology & Vascular Therapies					
UNITED STATES	$ 586	$ 499	17.5 %	— %	17.5 %
INTERNATIONAL	746	679	9.9 %	(1.7)%	8.2 %
WORLDWIDE	**$ 1,333**	**$ 1,178**	**13.1 %**	**(1.0)%**	**12.1 %**
Watchman					
UNITED STATES	$ 459	$ 446	3.0 %	— %	3.0 %
INTERNATIONAL	48	40	19.3 %	(1.5)%	17.7 %
WORLDWIDE	**$ 507**	**$ 486**	**4.3 %**	**(0.1)%**	**4.2 %**
Electrophysiology					
UNITED STATES	$ 606	$ 587	3.1 %	— %	3.1 %
INTERNATIONAL	310	252	22.9 %	0.2 %	23.1 %
WORLDWIDE	**$ 916**	**$ 840**	**9.1 %**	**0.0 %**	**9.1 %**
Cardiac Rhythm Management					
UNITED STATES	$ 349	$ 355	(1.7)%	— %	(1.7)%
INTERNATIONAL	236	235	0.3 %	(1.9)%	(1.6)%
WORLDWIDE	**$ 585**	**$ 590**	**(0.9)%**	**(0.8)%**	**(1.6)%**
Interventional Oncology & Embolization					
UNITED STATES	$ 175	$ 155	12.8 %	— %	12.8 %
INTERNATIONAL	108	96	12.9 %	(2.9)%	10.0 %
WORLDWIDE	**$ 283**	**$ 251**	**12.9 %**	**(1.1)%**	**11.8 %**
CARDIOVASCULAR					
UNITED STATES	$ 2,175	$ 2,042	6.5 %	— %	6.5 %
INTERNATIONAL	1,449	1,303	11.2 %	(1.5)%	9.8 %
WORLDWIDE	**$ 3,624**	**$ 3,345**	**8.3 %**	**(0.6)%**	**7.8 %**

Appendix B
Additional Information - Statement of Operations

Appendix B - Statement of Operations
Profitability Margins

Adjusted Gross Margin	Three Months Ended 6/30/2026	Three Months Ended 6/30/2025	Basis Points Change
Gross Margin, as reported	**70.7 %**	**67.7 %**	**300**
Non-GAAP adjustments	(0.4)%	1.7 %	
Gross Margin, adjusted	**70.3 %**	**69.4 %**	**80**

Adjusted Operating Margin	Three Months Ended 6/30/2026	Three Months Ended 6/30/2025	Basis Points Change
Operating Margin, as reported	**21.6 %**	**16.2 %**	**550**
Non-GAAP adjustments	6.7 %	11.4 %	
Operating Margin, adjusted	**28.4 %**	**27.6 %**	**70**

Appendix C
Additional Non-GAAP Reconciliations

Appendix C - Additional Non-GAAP Reconciliations

(in millions, except percentages)	Q2 2026	Q2 2025	As Reported Basis	Impact of Foreign Currency Fluctuations	Operational Basis	Impact of Certain Acquisitions/ Divestitures[1]	Organic Basis
ENDOSCOPY	$ 793	$ 737	7.6 %	(0.7)%	7.0 %	— %	7.0 %
UROLOGY	684	676	1.1 %	(0.3)%	0.8 %	— %	0.8 %
NEUROMODULATION	341	303	12.7 %	(0.6)%	12.2 %	— %	12.2 %
MEDSURG	**1,818**	**1,716**	**5.9 %**	**(0.5)%**	**5.4 %**	**— %**	**5.4 %**
INTERVENTIONAL CARDIOLOGY & VASCULAR THERAPIES	*1,333*	*1,178*	*13.1 %*	*(1.0)%*	*12.1 %*	*— %*	*12.1 %*
WATCHMAN	*507*	*486*	*4.3 %*	*(0.1)%*	*4.2 %*	*— %*	*4.2 %*
ELECTROPHYSIOLOGY	*916*	*840*	*9.1 %*	*0.0 %*	*9.1 %*	*— %*	*9.1 %*
CARDIAC RHYTHM MANAGEMENT	*585*	*590*	*(0.9)%*	*(0.8)%*	*(1.6)%*	*— %*	*(1.6)%*
INTERVENTIONAL ONCOLOGY & EMBOLIZATION	*283*	*251*	*12.9 %*	*(1.1)%*	*11.8 %*	*— %*	*11.8 %*
CARDIOVASCULAR	**3,624**	**3,345**	**8.3 %**	**(0.6)%**	**7.8 %**	**— %**	**7.8 %**
NET SALES	**$ 5,442**	**$ 5,061**	**7.5 %**	**(0.5)%**	**7.0 %**	**— %**	**7.0 %**

[1] There were no applicable acquisitions in the second quarter of 2026 or 2025.

Appendix C - Additional Non-GAAP Reconciliations

Boston Scientific

Free Cash Flow *(in millions)*		**Three Months Ended 6/30/2026**
Cash provided by (used for) operating activities	**$**	**1,475**
Proceeds on disposals of property, plant and equipment		10
Purchases of property, plant and equipment and internal use software		(194)
Free Cash Flow	**$**	**1,290**

Estimated Free Cash Flow *(in billions)*		**FY 2026**
Cash provided by (used for) operating activities	**$**	**~4.7**
Purchases of property, plant and equipment and internal use software		(0.9)
Free Cash Flow	**$**	**~3.8**

Appendix C - Additional Non-GAAP Reconciliations

Boston Scientific

Reconciliation of Debt to Adjusted EBITDA *(in millions)*	**Q3 2025**	**Q4 2025**	**Q1 2026**	**Q2 2026**	**12 Months Ended 6/30/2026**
Net income (loss)	**$ 755**	**$ 670**	**$ 1,339**	**$ 905**	**$ 3,668**
Income tax (benefit) expense	183	30	(176)	155	192
Interest expense	87	90	90	96	363
Interest income	(6)	(14)	(15)	(11)	(46)
Depreciation expense	117	137	118	122	494
Amortization expense	225	228	232	233	918
EBITDA	**1,362**	**1,141**	**1,588**	**1,500**	**$ 5,590**
Non-GAAP Adjustments					
Restructuring and restructuring-related net charges (credits)	36	97	35	42	210
Goodwill and other intangible asset impairment charges	0	—	—	—	0
Investment portfolio net losses (gains)	(6)	26	(137)	(2)	(120)
Acquisition/divestiture - related net charges (credits)	99	89	47	92	327
Litigation-related net charges (credits)	—	194	—	76	270
EU MDR implementation costs	11	12	7	7	37
IEEPA tariff refund	—	—	—	(83)	(83)
Adjusted EBITDA	**$ 1,502**	**$ 1,558**	**$ 1,540**	**$ 1,630**	**$ 6,230**
Debt					**$ 12,624**
Debt to Adjusted EBITDA					**2.0 X**

Appendix C - Additional Non-GAAP Reconciliations

Adjusted Operating Margin - by Reportable Segment *(in millions, except percentages)*	Three Months Ended June 30, 2026				
	MedSurg	% of net sales of reportable segments	Cardiovascular	% of net sales of reportable segments	Total
Net sales, as reported	**$ 1,818**		**$ 3,624**		**$ 5,442**
Impact of foreign currency fluctuations	(0)		(2)		(2)
Net sales of reportable segments	1,818		3,622		5,440
Segment expenses	$ 1,221	67.1 %	$ 2,425	66.9 %	
Adjusted operating income of reportable segments[1]	598	32.9 %	1,197	33.1 %	1,795
Unallocated amounts:					
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments					(252)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), EU MDR implementation costs, and the IEEPA tariff refund					(132)
Amortization expense					(233)
Operating income (loss), as reported					**$ 1,178**

[1] Calculated as Net sales of reportable segments less Segment expenses.

Appendix C - Additional Non-GAAP Reconciliations

Boston Scientific

Adjusted Operating Margin - by Reportable Segment *(in millions, except percentages)*	Three Months Ended June 30, 2025				
	MedSurg	% of net sales of reportable segments	**Cardiovascular**	% of net sales of reportable segments	**Total**
Net sales, as reported	**$ 1,716**		**$ 3,345**		**$ 5,061**
Impact of foreign currency fluctuations	9		20		29
Net sales of reportable segments	1,725		3,365		5,090
Segment expenses	1,119	64.9 %	2,286	67.9 %	
Adjusted operating income of reportable segments[1]	606	35.1 %	1,079	32.1 %	1,685
Unallocated amounts:					
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments					(286)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits) and EU MDR implementation costs					(355)
Amortization expense					(225)
Operating income (loss), as reported					**$ 819**

[1] Calculated as Net sales of reportable segments less Segment expenses.

Appendix C - Additional Non-GAAP Reconciliations

Adjusted Below-the-Line Expenses *(in millions)*		Three Months Ended June 30, 2026
Below-the-line expenses, as reported	**$**	**(118)**
Non-GAAP adjustments		(2)
Below-the-line expenses, adjusted	**$**	**(120)**

Adjusted Tax Rate	Three Months Ended June 30, 2026
Tax Rate, as reported	**14.6 %**
Non-GAAP adjustments	(4.2) %
Tax Rate, adjusted	**10.4 %**

Appendix C - Additional Non-GAAP Reconciliations

Interventional Cardiology Net Sales Growth *(in millions, except percentages)*	**Three Months Ended June 30, 2026**	
	$	**%**
Net sales growth, as reported	**$ 849**	**16.1 %**
Impact of foreign currency fluctuations	(8)	(1.1)%
Net sales growth, operational	**840**	**14.9 %**
Impact of certain acquisitions/divestitures	—	— %
Net sales growth, organic	**$ 840**	**14.9 %**

Vascular Therapies Net Sales Growth *(in millions, except percentages)*	**Three Months Ended June 30, 2026**	
	$	**%**
Net sales growth, as reported	**$ 484**	**8.4 %**
Impact of foreign currency fluctuations	(3)	(0.8)%
Net sales growth, operational	**481**	**7.6 %**
Impact of certain acquisitions/divestitures	—	— %
Net sales growth, organic	**$ 481**	**7.6 %**

Appendix C - Additional Non-GAAP Reconciliations

EP U.S. Net Sales Growth	Three Months Ended June 30, 2026
Net sales growth, as reported	**3.1 %**
Impact of foreign currency fluctuations	— %
Net sales growth, operational	**3.1 %**
Impact of certain acquisitions/divestitures	— %
Net sales growth, organic	**3.1 %**

EP International Net Sales Growth	Three Months Ended June 30, 2026
Net sales growth, as reported	**22.9 %**
Impact of foreign currency fluctuations	0.2 %
Net sales growth, operational	**23.1 %**
Impact of certain acquisitions/divestitures	— %
Net sales growth, organic	**23.1 %**

Watchman U.S. Net Sales Growth	Three Months Ended June 30, 2026
Net sales growth, as reported	**3.0 %**
Impact of foreign currency fluctuations	— %
Net sales growth, operational	**3.0 %**
Impact of certain acquisitions/divestitures	— %
Net sales growth, organic	**3.0 %**

Watchman International Net Sales Growth	Three Months Ended June 30, 2026
Net sales growth, as reported	**19.3 %**
Impact of foreign currency fluctuations	(1.5)%
Net sales growth, operational	**17.7 %**
Impact of certain acquisitions/divestitures	— %
Net sales growth, organic	**17.7 %**

Appendix C - Additional Non-GAAP Reconciliations

Net Sales Guidance	Q3 2026 Estimate (Low)	Q3 2026 Estimate (High)	Full Year 2026 Estimate (Low)	Full Year 2026 Estimate (High)
Reported growth	**3.0 %**	**5.0 %**	**5.5 %**	**6.5 %**
Impact of foreign currency fluctuations	— %	— %	(0.5) %	(0.5) %
Operational growth	**3.0 %**	**5.0 %**	**5.0 %**	**6.0 %**
Impact of certain acquisitions/divestitures	— %	— %	— %	— %
Organic growth	**3.0 %**	**5.0 %**	**5.0 %**	**6.0 %**

Earnings per Share Guidance	Q3 2026 Estimate (Low)	Q3 2026 Estimate (High)	Full Year 2026 Estimate (Low)	Full Year 2026 Estimate (High)
Adjusted results[1]	$ 0.80	$ 0.82	$ 3.28	$ 3.32

Estimated Adjusted Below-the-Line Expenses *(in millions)*	Full Year 2026 Estimate
Below-the-line expenses, adjusted[1]	$ ~485

Estimated Tax Rate	Full Year 2026 Estimate
Tax Rate, adjusted[1]	~11.5%

Estimated Other Business Units Net Sales Growth	2H 2026 Estimate
Net sales growth, organic[1]	~6%

Estimated EP International Net Sales Growth	Full Year 2026 Estimate
Net sales growth, organic[1]	~20%

[1] The company has not provided reconciliations of certain forward-looking adjusted metrics to their respective GAAP measure as it is unable to predict with reasonable certainty and without unreasonable efforts the impact of certain items such as intangible asset impairment charges, acquisition-related charges, restructuring and restructuring-related charges and litigation-related charges, among other items. The combined impact of these items is uncertain, dependent on various factors and cannot be predicted with reasonable certainty, and could be material to our GAAP measures of financial results.

BSX: Acronym Reference Guide

AF	Atrial Fibrillation
CODM	Chief Operating Decision Maker
CRM	Cardiac Rhythm Management
DCB	Drug Coated Balloon
DIOH	Days Inventory on Hand
DRG	Diagnosis-Related Group Reimbursement
DSO	Days Sales Outstanding
EBITDA	Earnings Before Interest, Taxes, Depreciation, and
EMEA	Europe, the Middle East and Africa
Endo	Endoscopy
EP	Electrophysiology
EPS	Earnings per Share
ERG	Employee Resource Group
ESG	Endoscopic Sleeve Gastroplasty
EU MDR	European Union Medical Device Regulation
FDA	Food and Drug Administration
FY	Full Year
GAAP	Generally Accepted Accounting Principles
ICVT	Interventional Cardiology & Vascular Therapies
IEEPA	International Emergency Economic Powers Act
IO&E	Interventional Oncology & Embolization
IVL	Intravascular Lithotripsy
LAAC	Left Atrial Appendage Closure
LEED	Leadership in Energy and Environmental Design
NM	Neuromodulation
PCI	Percutaneous Coronary Intervention
PFA	Pulsed Field Ablation
PMDA	Pharmaceuticals and Medical Device Agency
PNS	Peripheral Nerve Stimulation
R&D	Research and Development
SCS	Spinal Cord Stimulation
TCT	Transcatheter Cardiovascular Therapeutics
TAVR	Transcatheter Aortic Valve Replacement
TCAR	Transcarotid Artery Revascularization
VBP	Volume-based Procurement
WM	Watchman